NANJING, China, 2 september 2024 /PRNewswire/ — Op 2 september 2024 kondigde Simcere Zaiming, een innovatief oncologiebedrijf onder Simcere Pharmaceutical Group (2096.HK), een samenwerkingsovereenkomst aan met Shenzhen TargetRx Inc. De samenwerking richt zich op de ALK/ROS1 dual receptor…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.